

TABLE OF CONTENTS

Acknowledgments..... xi

Introduction xiii

1 The Clinical Research Coordinator (CRC)..... 1

 Background and Training of the CRC..... 1

 Personality and Skills..... 2

 Where Do CRCs Work? 2

 CRC Responsibilities..... 4

 Problems and Opportunities 7

2 Institutional Review Boards (IRBs) and Data Safety Monitoring Boards (DSMBs).....9

 Introduction 9

 Types of IRBs..... 10

 IRB Membership..... 10

 IRB Operations..... 11

 IRB Responsibilities 11

 Vulnerable Subjects 12

 State and Local Regulations 13

 IRB Review of Proposed Research 13

 Materials Submitted to the IRB by an Investigator..... 13

 IRB Deliberations 15

 Investigator Reporting Responsibilities..... 15

 Continuing Review of a Research Study 16

 Expedited Review 17

Conflict of Interest.....	17
IRB Registration.....	18
FDA Guidance Documents for IRBs.....	18
CRC Duties and Responsibilities.....	19
Data Safety Monitoring Boards (DSMBs).....	19
Key Takeaways.....	21
Case Study: Conflict of Interest.....	22
Discussion.....	22

3 Informed Consent.....23

Introduction.....	23
Defining Informed Consent.....	23
Preparing the Informed Consent Document.....	24
Obtaining Informed Consent.....	28
The Consent Process.....	30
Exceptions from Consent.....	31
Conclusion.....	34
Key Takeaways.....	35

4 Regulations and Good Clinical Practices (GCPs)37

Introduction.....	37
FDA Regulations for Clinical Trials.....	37
ICH Guideline for Good Clinical Practice.....	38
FDA Guidelines and Information Sheets.....	38
FDA Compliance Program Guidance Manuals.....	39
NIH-Regulated Research.....	39
FDA Bioresearch Monitoring Program (BIMO).....	40
Good Clinical Practice (GCP).....	40
Contacting the FDA.....	41
HIPAA.....	41
HIPAA Authorization.....	41
Protected Health Information (PHI).....	42
Recruitment of Study Subjects.....	43
Obtaining Informed Consent under HIPAA.....	45

	The Declaration of Helsinki (1964)	45
	The Belmont Report (1979).....	46
	Key Takeaways	46
5	An Overview of Research	49
	Introduction	49
	Pre-Clinical Research	49
	Clinical Trials	52
	Notes on Studies in Women and Children	56
	Summary	57
	Key Takeaways	58
6	Devices and Biologics.....	59
	Biologics and Vaccines.....	61
	Key Takeaways	63
7	Standard Operating Procedures (SOPs).....	65
	Writing SOPs.....	66
	Approval, Training and Implementation	71
	SOPs for Investigative Sites.....	71
	Key Takeaways	75
	Case Study: Why do we need SOPs?	77
8	Preparing for a Study	79
	Introduction	79
	Site Assessments (Site Evaluations).....	79
	How to Succeed in Getting Studies.....	81
	Protocol Feasibility.....	82
	Grants, Budgeting and Contracts	83
	Investigative Site Study Files	86
	Storage of Study Materials.....	90
	Study Documents	91
	Financial Disclosure	92
	Investigator Meetings	94

Study Initiation Meetings.....	95
Working with CRAs	96
Other Sponsor Interactions	97
Shipping of Biological Samples.....	97
Key Takeaways	98
9 Protocols	101
Introduction	101
Protocols.....	101
Protocol Complexity.....	109
Protocol Amendments.....	110
During the Study.....	111
Key Takeaways.....	112
Case Study: Protocols	114
10 Case Report Forms (CRFs) and Electronic Data Capture (EDC)	115
Case Report Forms (CRFs)	115
Electronic Data Capture (EDC).....	120
Good, High-Quality Data.....	121
Internal Quality Assurance.....	122
Key Takeaways.....	122
Case Study: The Cost of Errors	123
11 Investigational Product Accountability.....	125
Responsibilities	125
During a Clinical Trial	127
Key Takeaways.....	128
Case Study: Investigational Product Accountability.....	128
12 Working with Study Subjects	131
Recruitment of Study Subjects.....	131
New Strategies for Subject Recruitment	138
Scheduling Subjects	143

Retention of Study Subjects.....	145
Subject Compliance.....	150
Key Takeaways.....	155
13 Study Closure.....	159
Introduction.....	159
Reasons for Study Closure.....	159
Closure Procedures.....	160
Investigator’s Final Report to the Sponsor and the IRB.....	161
Administrative Issues.....	161
Record Retention.....	162
Post-Study Critique.....	163
Key Takeaways.....	164
14 Adverse Events (AEs) and Safety Monitoring.....	165
Regulations.....	165
Definitions.....	167
Adverse Events (AEs) on Marketed Products.....	168
Adverse Events (AEs) in Clinical Trials.....	169
Investigator Reporting Responsibilities.....	173
Sponsor Responsibilities.....	173
Differences Between Clinical Studies and Clinical Practice.....	174
Assessing the Relationship of an AE to the Study Drug.....	175
Common Reporting Problems.....	176
Key Takeaways.....	177
Case Study: Caught in the Middle with Adverse Events.....	178
15 Audits.....	179
Sponsor Audits of Investigative Sites.....	179
IRB Audits of Investigative Sites.....	181
FDA Audits of Investigative Sites.....	181
Consequences.....	189
Key Takeaways.....	190
Case Study: Audit Attitude.....	191

Afterword.....	193
Appendix A Acronyms	195
Appendix B Glossary.....	197
Appendix C Resources	203
Appendix D Sample Forms, Checklists and Logs	207
Appendix E Title 21—Food and Drugs	245
Part 11—Electronic Records; Electronic Signatures.....	245
Part 50—Protection Of Human Subjects.....	249
Part 54—Financial Disclosure by Clinical Investigators.....	262
Part 56—Institutional Review Boards.....	266
Part 312—Investigational New Drug Applicaion	276
Part 314—Applications for FDA Approval to market a new drug	321
Part 600—Biological Products: General	415
Part 601—Licensing.....	433
Part 610—General Biological Products Standards.....	463
Part 812—Investigational Device Exemptions	489
Part 814—Premarket Approval of Medical Devices.....	509
Appendix F Harmonized Tripartite Guideline for Good Clinical Practice.....	539
Appendix G Practice Examination	549
Index.....	563
About CenterWatch	567
About the Author	573